Themis nabs U.K. government funding for Chikungunya vaccine

Abnormal shifts in temperature throughout late 2016 and early 2017 are affecting the pest-control game.
Themis secured 3 million British pounds of funding from Innovate UK for its Chikungunya vaccine project.

After offering £1 million last September to help move Themis’ Zika candidate into the clinic, the U.K. government innovation agency, Innovate UK, has injected new funding of £3 million into the biotech's Chikungunya vaccine project.

With an eye on late-stage testing, the Austrian vaccine specialist has also tapped the U.K.’s National Institute for Biological Standards and Control to develop a non-human primate challenge model for analyzing human serum, according to an announcement. After that, as preparation for a large-scale phase 3 study, the team will conduct a small phase 1 trial in the U.K. to validate the vaccine’s correlate of protection and to identify a protective antibody threshold against the Chikungunya virus.

The vaccine is already undergoing three parallel phase 2 trials in central Europe, the U.S. mainland and, most recently and with assistance from the Walter Reed Army Institute of Research, in Puerto Rico, an endemic area. All told, 700 participants will receive the vaccine in those studies.

Cambrex Webinar

Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays

Wednesday, May 27, 2020 | 10am ET / 7am PT

A well-developed crystallization process can produce suitable particles that can facilitate consistent filtration, drying and formulation of the API and allow confident and reliable manufacturing of the final drug product, while avoiding unnecessary cost, risk and development delays.

RELATED: Chikungunya vaccines: Themis, Bharat Biotech kick off new testing

Themis plans to share first results from the phase 2 program at the upcoming American Society of Tropical Medicine & Hygiene annual meeting in Baltimore, Themis CEO Erich Tauber told FiercePharma on Tuesday. Tauber said his company is discussing the clinical pathway to licensure with the EMA and the FDA. With all of the resources available to Themis right now, phase 3 manufacturing will likely start early next year, the helmsman added.

Themis’ live attenuated vaccine uses a platform developed with measles vaccine as the vector. The company, which licensed the technology from the Pasteur Institute, says the platform allows a rapid upscaling of a cost-effective vaccine production process and has a proven efficacy and safety profile. It is also applied in a Zika vaccine candidate currently in a phase 1 study at the Medical University of Vienna.

Besides Themis, India’s Bharat Biotech, California-based PaxVax, an alliance between Zydus Cadila and Takeda, as well as the U.S. Army are all developing Chikungunya vaccine candidates.

Suggested Articles

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.

AZ is among the companies leading the COVID-19 vaccine race, and after agreeing first to supply the U.K., it's now in talks for delivery worldwide.